Where Gross-to-net Pressure Actually Lives After Launch

Today’s guest post comes from Cindy Baksh, Chief Product Officer at ConnectiveRx. Cindy explains that many gross-to-net (GTN) exposures now occur at the claim level, where evolving payer tactics, pharmacy economics, and copay complexity create unpredictable leakage. She argues that manufacturers mus

By Drug Channels · May 1, 2026 · via Drug Channels

This is an aggregated industry headline. Read the full story at Drug Channels →

RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.